Induction Chemoimmunotherapy Followed by Consolidative Hypofractionated Radiotherapy for Unresectable Locally Advanced NSCLC: A Real-World Outcomes Analysis
Cancers · 23.06.2026 · 18 (13) · 2036
DOI: 10.3390/cancers18132036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 23.06.2026. Verfasst von Caglayan Selenge Beduk Esen und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, American Hospital, Istanbul 34365, Türkiye. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose/Objective: To evaluate the safety and failure patterns of consolidative hypofractionated thoracic radiotherapy (RT) following induction chemoimmunotherapy in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). Materials/Methods: This retrospective study included 34 patients treated between 2019 and 2025. All patients received induction chemoimmunotherapy followed by consolidative hypofractionated RT based on multidisciplinary tumor board recommendations. The primary endpoint was local recurrence (LR); secondary endpoints were regional recurrence (RR), distant metastasis (DM), overall survival (OS), progression-free survival (PFS), and treatment-related toxicity.
Results
Median age was 64 years, and median PD-L1 expression was 20%. Most patients had stage III disease; squamous cell carcinoma (56%) and adenocarcinoma (38%) were the predominant histologies. The most common systemic regimen was carboplatin/paclitaxel plus nivolumab, with a median of four induction cycles. Post-induction response was complete in 21%, partial in 62%, stable in 12%, and progressive in 6%. Median RT dose was 52.5 Gy in 15 fractions, and maintenance immunotherapy was administered in 79%. At a median follow-up of 16.7 months, using cumulative incidence functions with death treated as a competing event, the 1- and 2-year cumulative incidences of local failure were 6.9% and 14.7%, respectively. The corresponding cumulative incidences of regional failure were 10.2% and 18.8%, while distant metastasis incidences were 15.9% and 39.2%. No isolated local or regional recurrences occurred. One- and two-year OS rates were 86% and 81%, and corresponding PFS rates were 76% and 54%. No grade 4–5 RT-related toxicity occurred; one grade 5 immune-related pneumonitis was observed.
Conclusions
Consolidative hypofractionated RT following chemoimmunotherapy appears feasible and associated with favorable outcomes, supporting further prospective investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, American Hospital, Istanbul 34365, Türkiye.
- Department of Radiation Oncology, Koç University School of Medicine, Istanbul 34450, Türkiye.
- Department of Medical Oncology, Koç University School of Medicine, Istanbul 34450, Türkiye.
- Department of Medical Oncology, American Hospital, Istanbul 34365, Türkiye.
- Department of Pulmonary Medicine, American Hospital, Istanbul 34365, Türkiye.
- Department of Thoracic Surgery, American Hospital, Istanbul 34365, Türkiye.
ORCID-Profile: Melis Selek, Merve Duman, Ugur Selek
Zitieren
APA
Beduk Esen, C. S., Celikarslan, S., Sezen, D., Selcukbiricik, F., Kaban, K., Kanitez, M., Yumuk, P. F., Molinas Mandel, N., Tabak, L., Cesur, E., Erus, S., Tanju, S., Dilege, S., Gumus, T., Atasoy, C., Demirkurek, C., Falay, O., Demirkol, M. O., Bulutay, P., …, & Selek, U. (2026). Induction Chemoimmunotherapy Followed by Consolidative Hypofractionated Radiotherapy for Unresectable Locally Advanced NSCLC: A Real-World Outcomes Analysis. Cancers, 18(13), 2036. https://doi.org/10.3390/cancers18132036
Vancouver
Beduk Esen CS, Celikarslan S, Sezen D, Selcukbiricik F, Kaban K, Kanitez M, et al. Induction Chemoimmunotherapy Followed by Consolidative Hypofractionated Radiotherapy for Unresectable Locally Advanced NSCLC: A Real-World Outcomes Analysis. Cancers. 2026;18(13):2036. doi:10.3390/cancers18132036
BibTeX
@article{BedukEsen2026,
author = {Beduk Esen, Caglayan Selenge and Celikarslan, Sukran and Sezen, Duygu and Selcukbiricik, Fatih and Kaban, Kerim and Kanitez, Metin and Yumuk, Perran Fulden and Molinas Mandel, Nil and Tabak, Levent and Cesur, Ezgi and Erus, Suat and Tanju, Serhan and Dilege, Sukru and Gumus, Terman and Atasoy, Cetin and Demirkurek, Cengiz and Falay, Okan and Demirkol, Mehmet Onur and Bulutay, Pinar and Firat, Pinar and Selek, Melis and Duman, Merve and Mohammadipour, Sepideh and Oymak, Saliha Ezgi and Kilic Durankus, Nulifer and Atagun, Yasemin and Selek, Ugur},
title = {Induction Chemoimmunotherapy Followed by Consolidative Hypofractionated Radiotherapy for Unresectable Locally Advanced NSCLC: A Real-World Outcomes Analysis},
journal = {Cancers},
year = {2026},
volume = {18},
number = {13},
pages = {2036},
doi = {10.3390/cancers18132036}
}
EUVIMED